Inmune Bio Inc (INMB) Stock Price, Quote & News

Company Profile

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of b...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 964 3720

Website: www.inmunebio.com

Address:

225 NE Mizner Blvd., Suite 640, Boca Raton, United States

TraderNice Aug. 6 at 5:23 PM

$INMB per Ortex, live short interest is 38.23! The stock is going to squeeze with enough volume

0 · Reply

Mjcwo Aug. 6 at 5:19 PM

$INMB chatter heating up on Reddit &amp; WSB — short squeeze fuel incoming. Shorts still hanging on, but one well-timed PR during earnings tomorrow could ignite fireworks. Don’t sleep on this sleeper. $XBI $MRNA $BMRN $VIR #biotech #shortsqueeze 🔥🔥

2 · Reply

Skywalker86 Aug. 6 at 4:15 PM

$INMB 👀

1 · Reply

Skywalker86 Aug. 6 at 4:12 PM

$INMB something to look out for 👀 https://www.businessinsider.com/short-squeeze-stock-market-meme-stocks-retail-investors-25-8

0 · Reply

TraderNice Aug. 6 at 4:02 PM

$INMB The market might be a red day tomorrow because of the tariff’s deadline for many countries. The one think that helps this stock is the Earning Call is after hours. Investors are looking for more in depth information on Phase 1-2, PARTNERSHIPS and guidance concerning financial.

1 · Reply

TraderNice Aug. 6 at 3:01 PM

$INMB no volume…more consolidation

0 · Reply

TraderNice Aug. 6 at 2:14 PM

$INMB INMB's earnings call is scheduled for Thursday, August 7th at 4:30 PM ET and anticipation is building.

1 · Reply

Mjcwo Aug. 6 at 2:08 PM

$INMB expecting positive updates during earnings tomorrow, hugely undervalued and beat down…ready for a pop.

0 · Reply

TraderNice Aug. 6 at 1:12 PM

$INMB This stock has a short interest of 37.87% Potential Implications Traders may be positioning themselves against INMB due to fundamental analysis, recent news, or technical indicators. However, given the substantial short interest and borrowing costs, any positive catalyst (such as earnings announcements, FDA updates, or strategic partnerships) could swiftly propel the price upward.

1 · Reply

The_Fifteen_Percent_Guy Aug. 6 at 11:51 AM

$TNON & $BTAI two absolute bangers after cutting $INMB at a 3% loss. Regular programming has resumed 💰 📺 If you didn't take 30% profits on BTAI this premarket, I think she still has a good shot at 4+ today after open, but let's see how she builds into the open. >>>

0 · Reply

INmune Bio's CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment

Jul 31, 2025, 7:00 AM EDT - 6 days ago

INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th

Jul 29, 2025, 7:00 AM EDT - 8 days ago

INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer's Association International Conference

Jul 4, 2025, 11:48 PM EDT - 4 weeks ago

INmune Bio: Thinking Through XPro's MINDFuL Data In Early Alzheimer's

Jul 4, 2025, 9:20 AM EDT - 4 weeks ago

'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday

Jun 30, 2025, 4:05 PM EDT - 5 weeks ago

INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 30, 2025, 11:52 AM EDT - 5 weeks ago

Alzheimer's Setback Hits INmune Bio Stock, But FDA Hopes Remain

Jun 30, 2025, 7:36 AM EDT - 5 weeks ago

INmune Bio's Alzheimer's drug fails to meet main goal in mid-stage study

Jun 30, 2025, 7:30 AM EDT - 5 weeks ago

INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer's Disease

Jun 27, 2025, 4:50 PM EDT - 5 weeks ago

INmune Bio: Finding Pay Dirt In Alzheimer's?

Jun 27, 2025, 12:16 PM EDT - 5 weeks ago

INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 27, 2025, 10:38 AM EDT - 5 weeks ago

INmune Bio Stock Soars Friday On Alzheimer's Treatment Hopes

Jun 26, 2025, 4:00 PM EDT - 5 weeks ago

INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer's on Monday, June 30th

Jun 16, 2025, 11:29 AM EDT - 7 weeks ago

INmune Bio: Imminent Phase 2 Alzheimer's Readout Of Unique Asset Presents Interesting Speculative Opportunity

May 15, 2025, 5:28 PM EDT - 2 months ago

INmune Bio: XPro Trial Readout In Alzheimer's Disease Offers Big Opportunity

May 10, 2025, 3:57 AM EDT - 3 months ago

INmune Bio, Inc. (INMB) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:10 PM EDT - 3 months ago

INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update

May 5, 2025, 7:00 AM EDT - 3 months ago

INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th

Apr 14, 2025, 8:00 AM EDT - 4 months ago

INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness

Mar 27, 2025, 8:15 PM EDT - 4 months ago

INmune Bio, Inc. (INMB) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:05 PM EDT - 4 months ago

INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

Mar 21, 2025, 1:15 PM EDT - 4 months ago

Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West +

PNW PRI

Mar 18, 2025, 4:31 PM EDT - 5 months ago

INmune Bio: CORDstrom Is A Game-Changer, As Investors Await Alzheimer's Results

Feb 12, 2025, 7:00 AM EST - 6 months ago

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer

Feb 10, 2025, 7:00 AM EST - 6 months ago

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Jan 2, 2025, 8:52 AM EST - 7 months ago

INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025

Dec 30, 2024, 3:20 PM EST - 7 months ago

INmune Bio: XPro Cognitive Readout In Sight, But Mind The Financial Dangers

Dec 4, 2024, 9:00 AM EST - 8 months ago

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower

Oct 31, 2024, 8:09 PM EDT - 9 months ago

INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 4:05 PM EDT - 9 months ago

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

Oct 28, 2024, 8:00 AM EDT - 10 months ago

INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB

Oct 24, 2024, 3:03 PM EDT - 10 months ago

INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination

Oct 24, 2024, 9:30 AM EDT - 10 months ago

INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024

Oct 11, 2024, 8:30 AM EDT - 10 months ago

INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit

Sep 30, 2024, 5:04 AM EDT - 11 months ago

INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal

Sep 26, 2024, 8:00 AM EDT - 11 months ago

INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort

Sep 17, 2024, 8:30 AM EDT - 11 months ago

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

Sep 13, 2024, 8:30 AM EDT - 11 months ago

INmune Bio Announces $13.0 Million Registered Direct Offering

Sep 3, 2024, 9:00 AM EDT - 1 year ago

INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference

Aug 1, 2024, 11:50 PM EDT - 1 year ago

INmune Bio, Inc. (INMB) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:05 PM EDT - 1 year ago

INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update

Jul 29, 2024, 9:00 AM EDT - 1 year ago

INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer's Patients

Jul 25, 2024, 8:00 AM EDT - 1 year ago

INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024

Jul 23, 2024, 8:45 AM EDT - 1 year ago

INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer

Jul 8, 2024, 6:12 AM EDT - 1 year ago

INmune Bio: Promising Phase 2 Trials For Alzheimer's Drug XPro

Jul 5, 2024, 9:57 AM EDT - 1 year ago

INmune Bio: Still A Bargain If Their Alzheimer's Program Reaches Its Inflection

May 30, 2024, 8:00 AM EDT - 1 year ago

INmune Bio Inc. to Join Russell 3000® Index

May 11, 2024, 8:58 PM EDT - 1 year ago

INmune Bio, Inc. (INMB) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:05 PM EDT - 1 year ago

INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update

May 7, 2024, 8:00 AM EDT - 1 year ago

INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9

TraderNice Aug. 6 at 5:23 PM

$INMB per Ortex, live short interest is 38.23! The stock is going to squeeze with enough volume

0 · Reply

Mjcwo Aug. 6 at 5:19 PM

2 · Reply

Skywalker86 Aug. 6 at 4:15 PM

$INMB 👀

1 · Reply

Skywalker86 Aug. 6 at 4:12 PM

$INMB something to look out for 👀 https://www.businessinsider.com/short-squeeze-stock-market-meme-stocks-retail-investors-25-8

0 · Reply

TraderNice Aug. 6 at 4:02 PM

1 · Reply

TraderNice Aug. 6 at 3:01 PM

$INMB no volume…more consolidation

0 · Reply

TraderNice Aug. 6 at 2:14 PM

$INMB INMB's earnings call is scheduled for Thursday, August 7th at 4:30 PM ET and anticipation is building.

1 · Reply

Mjcwo Aug. 6 at 2:08 PM

$INMB expecting positive updates during earnings tomorrow, hugely undervalued and beat down…ready for a pop.

0 · Reply

TraderNice Aug. 6 at 1:12 PM

1 · Reply

The_Fifteen_Percent_Guy Aug. 6 at 11:51 AM

0 · Reply

Bubbarayjr62 Aug. 5 at 11:55 PM

$INMB very nice comment on SA https://seekingalpha.com/article/4799344-inmune-bio-thinking-through-xpros-mindful-data-in-early-alzheimers#scroll_comments

1 · Reply

vyvai Aug. 5 at 9:51 PM

$INMB Its quite interesting with this drug. The more blood brain barrier is compromised (hence inflamation group showed better results) the better drug performs. Now main currently existing drugs of alzhaimer compromises blood brain barrier and XPro drug targets quite unique target hence can be used with other alzhaimer drugs. This drug is perfect for use in combination.

0 · Reply

10baggerPete Aug. 5 at 7:44 PM

$INMB cheer up ... They may not have a cure for altizmers but they have a thing for depression. Badly needed around here.

0 · Reply

TickerVoice Aug. 5 at 5:00 PM

$INMB ER gonna rip? shorts covered so many

1 · Reply

TraderNice Aug. 5 at 3:17 PM

$INMB The timing of the call, right after the AAIC presentation and before the publication, makes it a perfect opportunity for any partnership announcement or hints. This call could be a turning point. If they reveal a partner or outline a clear regulatory path, it might reignite investor interest. I’m no financial advisor for no one, but I’m waiting and hoping for NEW news on their partnership….we will see

0 · Reply

TraderNice Aug. 5 at 3:13 PM

$INMB Can we receive a catalyst Thursday? Certainly, August 7th at 4:30 PM ET marks the pivotal date for INmune Bio’s earnings call and corporate update. During this event, the company is anticipated to provide further insights into the following key areas: * XPro™ Alzheimer’s Drug: In-depth details regarding the drug’s development progress. * Phase 2 MINDFuL Trial Findings: Specifically, subgroup data showcasing cognitive and biological improvements. * Potential Pathways to FDA Breakthrough Therapy Designation: Clarification on the strategic steps being taken to achieve this designation. * Publication of Results: Explanation on how the findings will be presented in the upcoming peer-reviewed publication, which is scheduled for mid-August 3. * Strategic Partnership: INmune Bio has publicly indicated its active pursuit of a strategic partnership to expedite the development of XPro™.

0 · Reply

Btolz Aug. 5 at 2:10 PM

$INMB be really cool if this would run

1 · Reply

TraderNice Aug. 5 at 1:59 PM

$INMB We need a partnership soon!

1 · Reply

The_fight_dude Aug. 5 at 1:49 PM

$INMB

0 · Reply

Mjcwo Aug. 5 at 1:32 PM

$INMB

0 · Reply

Voric Aug. 5 at 9:29 AM

$INMB let's go

0 · Reply

SmallCapKing1 Aug. 5 at 6:13 AM

$INMB over 2 years of trading I have not seen this much shitty trading based on charts. Every other ticker with these kind of news would have seen at least 4.50. And this POS just dumps

4 · Reply

Market Cap	67.34M
Revenue (ttm)	10,000.00
Net Income (ttm)	-42.08M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-420,800.03%
Debt to Equity Ratio	0.00

Volume	1,068,106
Avg Vol	4,097,206
Day's Range	N/A - N/A
Shares Out	23.59M
Stochastic %K	30%
Beta	0.97
Analysts	Sell
Price Target	$9.65